In “MOM WARNS BIRTH CONTROL KILLED HER DAUGHTER”, ABC 7 WXYZ.COM, DETROIT, MI, reports on the recent funeral of S. Burns. The 25 year old died and was buried on Mother’s Day 2012, following an aneurysm. In the heart breaking video above, her surviving Mother, Natalie Rogers, explains that YAZ “was the only medication she was on” and that she believed she died from taking the #DROSPIRENONE (#DRSP) containing contraceptive.
The video above was broadcast on January 21, 2011, by “MARKETPLACE: Canada’s Consumer Watchdog”, and was entitled “Spinning A Pill”. The video feature is over 15 minutes and highlights the stories of several #DRSP #DROSPIRENONE survivors of pulmonary emboli. Sadly, it also includes the story of a family that lost a daughter to injuries from a #DRSP #DROSPIRENONE containing birth control pill while in a medical facility.
What makes the “Spinning A Pill” video particularly interesting is that fact that “MARKETPLACE: Canada’s Consumer Watchdog” shows how celebrities and athletes were used to promote use of #DRSP #DROSPIRENONE containing contraceptives. Basically, a popular actress, and athletes were utilized in a direct to consumer campaign to make these pills ‘top of mind’ choices to girls and women. In fact, the trademarked name “YASMIN”, the predecessor to “YAZ”, was emblazoned on the back of a professional volleyball players bikini bottom, and armband, so that it was prominently displayed. Similarly, a younger demographic was arguably targeted, through the public endorsement of a petite and fashionable actress who lauded how use of the pill put her in some form of ‘control’ over her body.
Granted, the above appear to have been efforts to convert Canadian users, or attract consumers to the #DRSP #DROSPIRENONE family of pills in, or from, Canadian markets. Aggressive marketing in the United States has been the subject of FDA Warning Letters, corrective advertising and payments of $20 Million Dollars to the Attorney Generals of 27 States. Regardless, the very ‘in your face’ marketing of these pills has allowed them to continue growing in popularity despite a growing body of scientific evidence, medical literature and open concern by the Food & Drug Administration (FDA).
As noted in prior posts, there are thousands of lawsuits, with estimates over 10,000, in the United States against the manufacturer of #DRSP #DROSPIRENONE containing birth control pills - BAYER HEALTHCARE PHARMACEUTICALS - alleging serious personal injuries and even death. Just this past week, during October 25, 2011 and October 27, 2011, two studies addressing the increased relative risk of blood clots these pills pose to users were released. Only last month, on September 26, 2011, FDA announced that it had only reached preliminary results of their ongoing evaluation of research and evidence on the risks posed by #DRSP #DROSPIRENONE birth controls pills and that it would convene a joint panel of experts on December 8, 2011, to evaluate this information and conduct public hearings. What does the future hold for #DRSP #DROSPIRENONE containing birth control users? How will the FDA act following these hearings and their own finding that these pills present a 1.74x risk of blood clot? We will see.
Despite the recent studies, repeated FDA action, the need for corrective advertisements, $20 Million in fines, and over 10,000 lawsuits, recently released reports indicate that the use and profit motive for #DRSP #DROSPIRENONE containing pills continues as the “YAZ franchise” reportedly grew 16.5%. Yet the entire “YAZ franchise” only seems to add a layer of additional risk to users, while older pills and generics, with a proven safety record remain on the pharmacy shelf. Why? How? Marketing across age groups ranging from early teens and up.
On October 24, 2011, the British Medical Journal, #BMJ, released yet another new study that provides insight into the higher risk of blood clots that #DRSP #DROSPIRENONE birth control pills, like #YASMIN, #YAZ, #BEYAZ, #SAFYRAL, and the generic equivalents pose to girls and women. This Danish cohort study, evaluated 1.3 Million women of similar age over nearly a decade. This study contributes to a growing body of scientific literature, and evidence, that #DRSP #DROSPIRENONE birth control pills pose a higher risk of blood clots to users than other forms of hormonal birth control pills. Estimates of the risk factor vary, but since 2009 studies published in the BMJ denote a higher risk than originally disclosed by the manufacturer in package warnings or direct to consumer advertising. The NYTimes “Prescriptions - The Business of Health Care” Blog featured this study on October 26, 2011 in “Study: YAZ has Higher Risks of Blood Clots” and provides relevant links and some analysis. The NYTimes blog also provides a direct link to the BMJ study. We have posted, over the past 2 years, all related BMJ links, news articles and other information “Yasmin & YAZ Claims/Lawsuits”.
The above video was the lead story ABC Nightline featured on October 14, 2011, regarding #DRSP #DROSPIRENONE survivor, C. Ubersox, following her bilateral pulmoni she claims were from #YAZ. This event resulted in her heart stopping, her being in a coma and remaining blind for life.
The following morning, on October 15, 2011, ABC’s Good Morning America (#GMA) reports on the dangers of #DRSP #DROSPIRENONE pills and cited #BAYER as stating they are safe and effective when used as directed. Yet, on September 26, 2011, the FDA scheduled public hearings for December 8, 2011, regarding continued concerns of blood clots, as well as emerging body of scientific evidence that #YASMIN #YAS or #DRSP #DROSPIRENONE birth control pills are blood clotting hazard of 1.5x to 3.0x more likely.
The Food & Drug Administration (FDA) has scheduled hearings for December 8, 2011, between a panel of experts to evaluate conflicting data, emerging scientific literature and evidence relating to the risk posed by #DRSP #DROSPIRENONE to consumers. On October, 27, 2011, FDA released, through FDA Office of Women’s Health, the final report of FDA funded study evaluating the risk of blood clots in users of several hormonal birth control products: “Report: Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints”. It is anticipated that FDA will present and discuss results relating to DRSP DROSPIRENONE containing birth control pills during the 12.8.11 joint meeting of the Reporductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.
It is estimated that over 10,000 girls and women have filed lawsuits claiming personal injuries from use of a #DRSP #DROSPIRENONE birth control pill. Injuries include allegations of death, strokes, deep vein thrombosis (DVT), pulmonary emboli (PE), cardiac events, pancreatitis and gallbladder dysfunction or removal.
Gabriel F. Zambrano, P.A., is the sponsor of this blog and commentary. Gabriel F. Zambrano, P.A., is an advocate of the dangers of #DRSP #DROSPIRENONE pills and posts related news @yazattorney @gfzambrano and @recallattorneys. Gabriel F. Zambrano, P.A. is actively investigating DRSP LAWSUITS, and representing women that suffered personal injuries from DROSPIRENONE containing birth controls pills. Gabriel F. Zambrano, P.A., is a member of the Federal MDL Discovery Committee, Representative Counsel or Co-Lead of several of the 1st 100 YAZ Bellwether Discovery Cases, Admitted Pro Hac Vice in the coordinated Mass Tort Proceedings in PA, that proudly represents survivors of DRSP injuries. Please REPOST.